Pneumonia · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Exacerbations · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Symptoms of dyspnoea · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes adverse events: candidiasis compared with placebo (very low certainty).
1 finding from 1 review
Withdrawal (all‐cause) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
Beclometasone showed no clear difference in withdrawal (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
FEV1 · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
It is very uncertain whether beclometasone changes mortality (all‐cause) (dichotomous Peto method) compared with placebo (very low certainty).
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Mortality (all‐cause) (dichotomous Peto method) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
It is very uncertain whether beclometasone/LABA changes mortality (all‐cause) (dichotomous Peto method) compared with LABA (very low certainty).
1 finding from 1 review
Pneumonia · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in pneumonia: participants with at least one (dichotomous Peto odds… compared with LABA (low certainty).
1 finding from 1 review
Exacerbations · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in exacerbations: participants with at least one (dichotomous) compared with LABA (moderate certainty).
1 finding from 1 review
Change in quality of life: SGRQ Scale: 0 to 100 · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Adverse events: candidiasis · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
1 finding from 1 review
Withdrawal (all‐cause) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
Beclometasone/LABA showed no clear difference in withdrawal (all‐cause) compared with LABA (moderate certainty).
1 finding from 1 review
Clinical response at 8 weeks · Patients with active or quiescent lymphocytic colitis
Beclometasone dipropionate showed no clear difference in clinical response at 8 weeks compared with mesalazine (low certainty).
1 finding from 1 review
Maintenance of clinical response · Patients with active or quiescent lymphocytic colitis
It is very uncertain whether beclometasone dipropionate changes maintenance of clinical response at 12 weeks compared with mesalazine (very low certainty).
1 finding from 1 review
Beclometasone dipropionate (systemic corticosteroid) vs Placebo or no treatment
Outcome not reported · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
The review found no eligible studies for this question.
1 finding from 1 review